Skip to main content

The U.S. Food and Drug Administration (FDA) has granted SuperGen, Inc. orphan drug designation for their targeted agent MP-470 in the treatment of glioblastoma multiforme.

Brain CancerConnect 490

MP-470 is a tyrosine kinase inhibitor targeted against c-MET, c-RET, and the Rad51 protein, as well as mutant forms of c-KIT, PDGFR, and FLT3.

MP-470 is now being evaluated in Phase I trials as both a single agent and in combination with chemotherapy for the treatment of solid tumors. A Phase Ib trial is evaluating its efficacy in glioblastoma.

Scroll to Continue

Recommended Articles

Brain Cancer Newsletter 490